ENDRA Life Sciences Inc. 8-K

What Happened

• ENDRA Life Sciences, Inc. (NDRA) filed an 8‑K on April 21, 2026 (Item 3.01) reporting that Nasdaq’s Listing Qualifications Staff notified the company on April 20, 2026 that it is no longer in compliance with Nasdaq’s minimum stockholders’ equity requirement of $2,500,000.
• The company’s Annual Report on Form 10‑K for the year ended December 31, 2025 reported stockholders’ equity of $2,260,120. ENDRA intends to timely request a hearing before the Nasdaq Hearings Panel to stay any delisting action while the appeal is pending.

Key Details

• Nasdaq minimum required stockholders’ equity: $2,500,000.
• ENDRA reported stockholders’ equity (12/31/2025): $2,260,120.
• Timeline highlights: initial Nasdaq notice May 27, 2025; compliance plan submitted July 11, 2025; regained compliance (subject to monitoring) on November 18, 2025; April 20, 2026 notice of non‑compliance.
• Company will request a hearing to seek a stay and is evaluating options to regain compliance, but stated there is no assurance it will succeed.

Why It Matters

• A Nasdaq delisting determination can materially affect shareholders by reducing liquidity, limiting access to capital markets, and potentially lowering the share price.
• The company’s immediate step—requesting a hearing—temporarily pauses Nasdaq action, but investors should monitor the outcome of the hearing and any remediation steps (e.g., capital raises, reverse stock split) the company pursues to restore compliance.